A Randomized, DBPC, Multi-National Phase II/III Study of the Safety and Efficacy of Two Doses of Sublingual Immunotherapy (SLIT) Administered as Allergen-Based Tablets Once Daily to Adult Patients Suffering From HDM Allergic Rhinitis.

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 01 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs S 524101 (Primary)
Indications Hypersensitivity; Perennial allergic rhinitis
Focus Registrational; Therapeutic Use

Most Recent Events

07 Mar 2016 Results from this and other trial (Clinical trial profile-213251) presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
05 Mar 2016 Results presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2016 Annual Meeting, according to a Stallergenes BV media release.
05 Mar 2016 Results published in a Stallergenes BV media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight